The global AI in cancer diagnostics market is anticipated to grow at a CAGR of 32.5% during the forecast period (2023-2030). Artificial Intelligence (AI) has made positive impact across various sectors including healthcare globally. A notable surge in the adoption of AI tools across different domains, including healthcare, has led to a pronounced increase in demand for AI-driven solutions and services within organizations.
Hence, this rapidly increasing interest has pushed healthcare industries to ramp up investment in AI and Machine Learning (ML)-based solutions, thus spurring growth and development within the market. For an instance, in May-2022, Therapixel launched MammoScreen 2D and 3D, an AI-based software that automatically analyzes mammograms and displays a summary report to radiologists, providing breast cancer detection and using prior exams to refine prediction.
Browse the full report description of “Artificial Intelligence in Cancer Diagnostics Market Size, Share & Trends Analysis Report by Application (Screening & Diagnosis, Tumor Identification and Surveillance), by type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Others (Cervical Cancer, blood cancer, bone cancer and other)), and by End User (Hospitals, Diagnostic centers, Research Organization, Medical Institute and academics), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/artificial-intelligence-in-cancer-diagnostics-market
In addition, the growing awareness of early cancer diagnostics drives the growth of AI in cancer diagnostics. The rise in the number of government programs to promote healthcare organizations along with healthcare providers to combine AI technologies in their hospitals for the betterment and advance the therapy of the patients. For instance, in May 2021, Quest Diagnostics and Paige announced a collaboration designed to unlock the potential of artificial intelligence (AI) to improve and speed the diagnosis of cancer and other diseases that rely on pathologic assessment. The collaboration involves analysis using Paige's proprietary machine learning expertise of pathology diagnostic data and digitized slides from Quest Diagnostics and its AmeriPath and Dermpath businesses to uncover markers of cancer and other diseases. Using these insights, the parties intend to develop new software products which, following regulatory approval, will be marketed to pathologists, oncologists and other providers to support disease diagnosis.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Application
o By Type
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes, IBM Corp., Intel Corp., Pfizer Inc., Microsoft Corp., Janssen Pharmaceuticals, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Artificial Intelligence in Cancer Diagnostics Market Report Segment
By Application
By Type
By End user
Global Artificial Intelligence in Cancer Diagnostics Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/artificial-intelligence-in-cancer-diagnostics-market